Grant: Fellowship - Priority Announcement - Inflammatory Bowel Disease
University of Calgary
$22,500.00
The role of epithelial protease-activated receptors (PARs) in regulating mediators of intestinal inflammation and cancer
FY 2009-10
Summary
Chronic inflammatory diseases are risk factors for the subsequent development of cancer in several organ systems. Specifically, the risk of developing colon cancer is higher in patients who have had extensive colitis (e.g. Crohn's disease or ulcerative colitis) for more than 10 years. The exact reason for this remains unknown, but it may in part reflect the ability of proinflammatory mediators, (e.g. interleukin (IL)-8, cyclooxygenase (COX)-2 and several of the metalloproteinase enzymes) to also stimulate pro-oncogenic processes, (i.e. cell survival, proliferation, invasion and new blood vessel formation). Our lab and others have found that protease-activated receptors (PARs), a family of cell surface receptors uniquely activated by proteolytic cleavage, can also contribute to both inflammatory and pro-oncogenic processes in the gut. Specifically, activation of one of these PARs, PAR2, can increase the expression of IL-8 and COX-2 in some cell lines. Furthermore, it appears that some of the effects of PAR2 activation are mediated through the transactivation of another receptor well-known for its role in cancer, the epidermal growth factor receptor. We are studying how PAR2 regulates the expression and activation of these proinflammatory/procancerous molecules to determine whether this is a major mechanism by which PARs contribute to the progression from inflammation to cancer. We also want to know whether PAR2 activation on epithelial cells affects the activity of other proteases in the gut, specifically, metalloproteinases. Proteolytic signalling cascades represent a major regulatory mechanism for these enzymes, but our understanding of how they influence disease, especially in the intestine, which is regularly exposed to multiple proteases (i.e. digestive and microbial), is still in its infancy. Ultimately, we think that targeting specific PARs on certain cell types may limit chronic inflammatory processes and help prevent subsequent development of cancer.
Department
Program
Fellowship - Priority Announcement - Inflammatory Bowel Disease
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
194284
Name
Hirota Christina L
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association of Gastroenterology (Oakville, Ontario)
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
The role of epithelial protease-activated receptors (PARs) in regulating mediators of intestinal inflammation and cancer
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$22,500
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement - Inflammatory Bowel Disease
Keyworddelim
Colitis; Colon Cancer; Cyclooxygenase; Epidermal Growth Factor Receptor; Epithelial Cell Biology; Metalloproteases; Molecular Biology; Protease-Activated Receptors
Abstract
Chronic inflammatory diseases are risk factors for the subsequent development of cancer in several organ systems. Specifically, the risk of developing colon cancer is higher in patients who have had extensive colitis (e.g. Crohn's disease or ulcerative colitis) for more than 10 years. The exact reason for this remains unknown, but it may in part reflect the ability of proinflammatory mediators, (e.g. interleukin (IL)-8, cyclooxygenase (COX)-2 and several of the metalloproteinase enzymes) to also stimulate pro-oncogenic processes, (i.e. cell survival, proliferation, invasion and new blood vessel formation). Our lab and others have found that protease-activated receptors (PARs), a family of cell surface receptors uniquely activated by proteolytic cleavage, can also contribute to both inflammatory and pro-oncogenic processes in the gut. Specifically, activation of one of these PARs, PAR2, can increase the expression of IL-8 and COX-2 in some cell lines. Furthermore, it appears that some of the effects of PAR2 activation are mediated through the transactivation of another receptor well-known for its role in cancer, the epidermal growth factor receptor. We are studying how PAR2 regulates the expression and activation of these proinflammatory/procancerous molecules to determine whether this is a major mechanism by which PARs contribute to the progression from inflammation to cancer. We also want to know whether PAR2 activation on epithelial cells affects the activity of other proteases in the gut, specifically, metalloproteinases. Proteolytic signalling cascades represent a major regulatory mechanism for these enzymes, but our understanding of how they influence disease, especially in the intestine, which is regularly exposed to multiple proteases (i.e. digestive and microbial), is still in its infancy. Ultimately, we think that targeting specific PARs on certain cell types may limit chronic inflammatory processes and help prevent subsequent development of cancer.
Competitiondate
200910
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hirota, Christina L
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Nutr Metabolism &Diab~ $22,500~ $0~